natgillin/translations-raw huggingface dataset:
The rapid onset and early peak of activity of insulin lispro is observed following the subcutaneous administration of Liprolog Mix25.
Nakon supkutane primjene lijeka Liprolog Mix25 djelovanje inzulina lispro počinje brzo i rano se postiže vršni učinak.
The rapid onset and early peak of activity of insulin lispro is observed following the subcutaneous administration of Liprolog Mix50.
Nakon supkutane primjene lijeka Liprolog Mix50 djelovanje inzulina lispro počinje brzo i rano se postiže vršni učinak.
The rapid onset and early peak of activity of Liprolog itself is observed following the subcutaneous administration of Liprolog Mix25.
Nakon supkutane primjene djelovanje lijeka Liprolog Mix25 počinje brzo i rano se postiže vršni učinak.
The rapid onset and early peak of activity of Liprolog itself is observed following the subcutaneous administration of Liprolog Mix50.
Nakon supkutane primjene djelovanje lijeka Liprolog Mix50 počinje brzo i rano se postiže vršni učinak.
The rapidity and extent of bacterial killing are directly proportional to the drug concentration.
Brzina i opseg ubijanja bakterija izravno su proporcionalni koncentraciji proizvoda.
The Raplixa spray device is connected to the ProFibrix pressure regulator and thereby to the medical gas supply set to a pressure setting of 1.5 bar (22 psi).
Uređaj RaplixaSpray se spaja na regulator tlaka ProFibrix, a time i na opskrbu medicinskim plinom s postavkom tlaka od 1,5 bara (22 psi).
The rapporteur acknowledges that these results may vary with the final analysis.
Izvjestitelj potvrđuje da se ti rezultati mogu razlikovati u konačnoj analizi.
The RAS mutant population consists of patients with known KRAS exon 2 mutations as well as additionally identified RAS mutations.
Populacija s mutiranim RAS-om sastoji se od bolesnika s poznatim mutacijama na eksonu 2 KRAS-a, kao i s naknadno utvrđenim mutacijama RAS-a.
The rate (95% confidence interval) of lymphomas was 0.7 (0.2, 2.7) per 1,000 patient-years among Humira-treated patients and 0.6 (0.1, 4.5) per 1,000 patient-years among control patients.
Limfomi su se javljali u stopi (interval pouzdanosti 95%) od 0,7 (0,2; 2,7) na 1000 bolesnik-godina u bolesnika liječenih lijekom Humira, odnosno u stopi od 0,6 (0,1; 4,5) na 1000 bolesnik-godina u kontrolnoj skupini.
The rate (95% confidence interval) of non-melanoma skin cancers was 8.8 (6.0, 13.0) per 1,000 patient-years among Humira-treated patients and 3.2 (1.3, 7.6) per 1,000 patient-years among control patients.
Stopa nemelanomskih tumora kože (interval pouzdanosti 95%) bila je 8,8 (6,0; 13,0) na 1000 bolesnik-godina u bolesnika liječenih lijekom Humira, odnosno 3,2 (1,3; 7,6) na 1000 bolesnik-godina u kontrolnoj skupini bolesnika.
The rate and extent of absorption of Onduarp are equivalent to the bioavailability of telmisartan and amlodipine when administered as individual tablets.
Brzina i opseg apsorpcije Onduarpa su ekvivalentni bioraspoloživosti telmisartana i amlodipina kada se primjenjuju zasebno.
The rate of administration should be determined by the patient’s comfort level (maximal rate of infusion: 2 ml/min).
Brzina primjene određuje se prema brzini koju bolesnik može podnijeti (maksimalna je brzina injiciranja 2 ml/min).
The rate of administration should be determined by the patient’s comfort level (maximal rate of infusion: 2 ml/min).
Brzina primjene određuje se prema stupnju tolerancije bolesnika (maksimalna je brzina infuzije 2 ml/min).
The rate of administration should be determined by the patient’s comfort level (maximal rate of infusion: mL/min).
Brzina primjene određuje se prema razini podnišljivosti bolesnika (maksimalna je brzina infuzije 2 ml/min).
The rate of administration should be determined by the patient’s comfort level (maximal rate of infusion: mL/min).
Brzina primjene određuje se prema razini podnošljivosti bolesnika (maksimalna je brzina infuzije 2 ml/min).
The rate of administration should be determined by the patient’s comfort level and should not exceed 10 mL/min.
Brzinu primjene treba odrediti prema razini ugode u bolesnika i ne smije biti veća od 10 ml/min.
The rate of administration should be determined by the patient’s comfort level, up to a maximum of 5 ml/min.
Brzinu primjene treba odrediti prema razini podnošljivosti u bolesnika, do najviše 5 ml/min..
The rate of administration should be determined by the patient’s comfort level.
Brzinu primjene treba odrediti tako da bolesniku bude ugodno.
The rate of administration should be determined by the patient’s comfort level.
Brzinu primjene treba podesiti na razinu koja je bolesniku ugodna.
The rate of ARRs of all grades varied between studies depending on the indication, the data collection methodology, and whether trastuzumab was given concurrently with chemotherapy or as monotherapy.
Stopa reakcija povezanih s primjenom lijeka svih stupnjeva varirala je od ispitivanja do ispitivanja ovisno o indikaciji, metodologiji prikupljanja podataka te o tome je li se trastuzumab primjenjivao u kombinaciji s kemoterapijom ili kao monoterapija.
The rate of atrial fibrillation serious adverse events was 1.3% (51 out of 3,862) and 0.6% (22 out of 3,852) in patients receiving zoledronic acid 5 mg and placebo, respectively.
Stopa fibrilacije atrija kao ozbiljnog štetnog događaja bila je 1,3% (51 od 3862) u bolesnica koje su primale zoledronatnu kiselinu u dozi od 5 mg, odnosno 0,6% (22 od 3852) u bolesnica koje su primale placebo.
The rate of atrial fibrillation serious adverse events was increased in patients receiving zoledronic acid (1.3%) (51 out of 3,862) compared with patients receiving placebo (0.6%) (22 out of 3,852).
Stopa ozbiljnih stetnih događaja fibrilacije atrija bila je veća u bolesnika koji su primali zoledronatnu kiselinu (1,3%) (51 od 3862), naspram bolesnika koji su primali placebo (0,6%) (22 od 3852).
The rate of clearance of the active metabolite, corrected for body- weight, decreases with ages below one year.
Brzina klirensa aktivnog metabolita, korigirana za tjelesnu težinu, smanjuje se s dobi manjom od jedne godine.
The rate of clinical events was substantially lower among Fabrazyme-treated patients compared to placebo-treated patients (risk reduction = 53% intent-to-treat population (p=0.0577); risk reduction = 61 % per-protocol population (p=0.0341)).
Stopa kliničkih događaja bila je znatno niža u bolesnika liječenih lijekom Fabrazyme nego u bolesnika koji su primali placebo (smanjenje rizika = 53% u populaciji svih uključenih bolesnika (p=0,0577); smanjenje rizika = 61% u populaciji prema realiziranom protokolu (p=0,0341)).
The rate of elimination of radium-223 dichloride from the gastrointestinal tract is influenced by the high variability in intestinal transit rates across the population, with the normal range from once daily to once weekly bowel evacuation.
Na brzinu eliminacije radij-223 diklorida iz probavnog trakta utječe velika varijabilnost brzine prolaska crijevnog sadržaja koja postoji u populaciji, uz normalni raspon pražnjenja crijeva od jedanput na dan do jedanput tjedno.
The rate of exacerbations (as defined in the protocols) were not significantly reduced by roflumilast in the individual studies (relative risk reduction: 13.5% in study M2-111 and 6.6% in study M2-112; p= not significant).
Stopa egzacerbacija (definiranih po protokolu) nije se u pojedinačnim ispitivanjima na roflumilastu značajno smanjila (relativno smanjenje rizika 13,5% u ispitivanju M2-111 i 6,6% u ispitivanju M2-112; p=nije značajno).
The rate of haematological response was 70 % with a duration of 2–3 months.
Stopa hematološkog odgovora bila je 70 % uz trajanje od 2 do 3 mjeseca.
The rate of haematological response was 70% with a duration of 2–3 months.
Stopa hematološkog odgovora bila je 70% uz trajanje od 2 do 3 mjeseca.
The rate of hepatocellular carcinoma was 18% (8/45) in the tenofovir disoproxil fumarate group, 7% (3/45) in the emtricitabine plus tenofovir disoproxil fumarate group and 9% (2/22) in the entecavir group.
Stopa hepatocelularnog karcinoma iznosila je 18% (8/45) u skupini liječenoj tenofovirdizoproksilfumaratom, 7% (3/45) u skupini liječenoj emtricitabinom i tenofovirdizoproksilfumaratom i 9% (2/22) u skupini liječenoj entekavirom.
The rate of herpes zoster was slightly higher in PV (6.4%) patients than in MF (4.0%) patients.
Stopa herpes zostera bila je neznatno viša u bolesnika s PV-om (6,4%) nego u bolesnika s MF-om (4,0%).
The rate of HIV-1 seroconversion in males was 0.24/100 person-years of Truvada exposure and the rate of HIV-1 seroconversion in females was 0.95/100 person-years of Truvada exposure.
Stopa serokonverzije HIV-1 u muškaraca iznosila je 0,24/100 osoba-godina izloženosti Truvadi, a stopa serokonverzije HIV-a u žena iznosila je 0,95/100 osoba-godina izloženosti Truvadi.
The rate of hypoglycaemic episodes (per patient year of exposure) was statistically significantly lower when adding liraglutide compared to adding a single dose of insulin aspart (1.0 vs 8.15; ratio: 0.13; 95% CI: 0.08 to 0.21).
Stopa epizoda hipoglikemija (po izloženosti bolesnik-godina) bila je statistički značajno niža kada je dodan liraglutid u odnosu na dodavanje jedne doze aspart inzulina (1,0 naspram 8,15, omjer: 0,13; 95% CI: 0,08 do 0,21).
The rate of increase in haemoglobin should be approximately 1 g/dl (0.62 mmol/l) per month and should not exceed 2 g/dl (1.25 mmol/l) per month to minimize the risk of developing or worsening of hypertension.
Brzina povećavanja razine hemoglobina trebala bi biti približno 1 g/dl (0,62 mmol/l) mjesečno i ne bi trebala prijeći 2 g/dl (1,25 mmol/l) mjesečno kako bi se smanjio rizik razvoja ili pogoršanja hipertenzije.
The rate of infection was 0.91 per patient-year of follow-up in ustekinumab-treated patients, and the rate of serious infections was 0.02 per patient-year of follow-up in ustekinumab-treated patients (178 serious infections in 10,953 patient-years of follow-up) and serious infections reported included anal abscess, cellulitis, pneumonia, diverticulitis, gastroenteritis and viral infections.
Stopa infekcije je bila 0,91 po bolesnik-godini praćenja bolesnika liječenih ustekinumabom, a stopa ozbiljnih infekcija bila je 0,02 po bolesnik-godini praćenja bolesnika liječenih ustekinumabom (178 ozbiljne infekcije u 10 953 bolesnik-godina praćenja), a zabilježene ozbiljne infekcije uključivale su analni apsces, celulitis, upalu pluća, divertikulitis, gastroenteritis i virusne infekcije.
The rate of infusion can be escalated in 50 mg/hr increments every 30 minutes to a maximum of 400 mg/hr.
Brzinu infuzije moguće je povećavati za 50 mg/h svakih 30 minuta do maksimalne brzine od 400 mg/h.
The rate of infusion can be escalated in increments of 50 mg/hr every 30 minutes to a maximum rate of 400 mg/hr.
Brzinu infuzije moguće je povećavati za 50 mg/h svakih 30 minuta do maksimalne brzine od 400 mg/h.
The rate of nocturnal hypoglycaemic events was significantly lower with Xultophy compared to insulin glargine (estimated treatment ratio 0.17, p<0.001).
Stopa noćnih hipoglikemijskih događaja bila je značajno niža uz Xultophy nego uz glargin inzulin (procijenjeni terapijski omjer: 0,17; p<0,001).
The rate of nocturnal hypoglycaemic events was similar with Xultophy and insulin degludec treatment.
Stopa noćnih hipoglikemijskih događaja bila je slična i uz liječenje lijekom Xultophy i uz liječenje degludek inzulinom.
The rate of pregabalin absorption is decreased when given with food resulting in a decrease in Cmax by approximately 25 – 30% and a delay in tmax to approximately 2.5 hours.
Brzina apsorpcije pregabalina smanjuje se kada se lijek primjenjuje s hranom, što dovodi do smanjenja Cmax za približno 25-30%, dok je tmax odgođen na približno 2,5 sata.
The rate of progression of structural damage in year 2 was significantly lower than that in year 1 for patients randomized to abatacept (p < 0.0001).
Brzina napredovanja strukturnog oštećenja je za bolesnike randomizirane na abatacept bila značajno manja u 2. nego u 1. godini (p < 0,0001).
The rate of responders (either a reduction in serum phosphorus ≤ 1.78 mmol/L and/or a reduction from baseline ≥ 0.3 mmol/L) was 50.4 % and 43.8% in the two studies, respectively (placebo 30.8% and 26.3%, respectively).
Brzina odgovora (smanjenje fosfora u serumu ≤ 1,78 mmol/l i/ili smanjenje u odnosu na početnu vrijednost ≥ 0,3 mmol/l) bila je 50,4 % odnosno 43,8% u ta dva ispitivanja (placebo 30,8% odnosno 26,3%).
The rate of the 30-day composite endpoint of death, myocardial re-infarction or intracranial haemorrhage (a measure of net clinical benefit) was significantly lower (p < 0.0001) in the enoxaparin group (10.1%) as compared to the heparin group (12.2%), representing a 17% relative risk reduction in favour of treatment with enoxaparin sodium.
Stopa mjere složenog ishoda (smrt, reinfarkt miokarda ili intrakranijalno krvarenje) nakon 30 dana (mjera čiste kliničke koristi) bila je značajno niža (p < 0,0001) u skupini koja je primala enoksaparin (10,1 %) u usporedbi sa skupinom koja je primala heparin (12,2 %), predstavljajući tako smanjenje relativnog rizika za 17 % u korist liječenja enoksaparinnatrijem.
The rate of the 30-day composite endpoint of death, myocardial re-infarction or intracranial haemorrhage (a measure of net clinical benefit) was significantly lower (p < 0.0001) in the enoxaparin group (10.1%) as compared to the heparin group (12.2%), representing a 17% relative risk reduction in favour of treatment with enoxaparin sodium.
Stopa mjere složenog ishoda (smrt, reinfarkt miokarda ili intrakranijalno krvarenje) nakon 30 dana (mjera čiste kliničke koristi) bila je značajno niža (p < 0,0001) u skupini koja je primala enoksaparin (10,1%) u usporedbi sa skupinom koja je primala heparin (12,2%), predstavljajući tako smanjenje relativnog rizika za 17% u korist liječenja enoksaparin-natrijem.
The rate of the 30-day composite endpoint of death, myocardial re-infarction or intracranial haemorrhage (a measure of net clinical benefit) was significantly lower (p < 0.0001) in the enoxaparin group (10.1%) as compared to the heparin group (12.2%), representing a 17% relative risk reduction in favour of treatment with enoxaparin sodium.
Stopa mjere složenog ishoda (smrt, reinfarkt miokarda ili intrakranijalno krvarenje) nakon 30 dana (mjera čiste kliničke koristi) bila je značajno niža (p < 0,0001) u skupini koja je primala enoksaparin (10,1%) u usporedbi sa skupinom koja je primala heparin (12,2%), predstavljajući tako smanjenje relativnog rizika za 17% u korist liječenja enoksaparinnatrijem.
The rate of the combination of MBEs/CRBEs and the rate of any bleeding was significantly lower at a nominal alpha level of 5 % in patients receiving placebo as compared with those receiving dabigatran etexilate.
Stopa kombinacije MBE/CRBE-a i stopa svakog krvarenja bila je značajno niža na nominalnoj alfa-razini 5% kod bolesnika na placebu u usporedbi sa bolesnicima na dabigatraneteksilatu.
The rate of the combination of MBEs/CRBEs and the rate of any bleeding was significantly lower at a nominal alpha level of 5 % in patients receiving placebo as compared with those receiving dabigatran etexilate.
Stopa kombinacije MBE/CRBE-a i svakog krvarenja bila je značajno niža na nominalnoj alfa-razini 5% kod bolesnika na placebu u usporedbi sa bolesnicima na dabigatranu.
The rate of TKV increase over 3 years was significantly less for tolvaptan-treated subjects than for subjects receiving placebo: 2.80% per year vs 5.51% per year, respectively (ratio of geometric mean 0.974; 95% CI 0.969 to 0.980; p < 0.0001).
Stopa porasta UVB-a tijekom 3 godine bila je značajno manja u ispitanika liječenih tolvaptanom nego u ispitanika koji su primali placebo: 2,80% godišnje naspram 5,51% godišnje (omjer geometrijske srednje vrijednosti 0,974; 95% CI od 0,969 do 0,980; p < 0,0001).
The rate of treatment success was statistically significantly higher for micafungin than fluconazole (1.6% versus 2.4% breakthrough infections).
Stopa uspjeha liječenja bila je statistički značajno viša za mikafungin nego za flukonazol (1,6% nasuprot 2,4% proboj infekcija).
The rate per 1,000 women years for transient ischaemic attacks (TIA) was similar between the 20 mg bazedoxifene (1.1) and placebo (0.88) groups and higher in the 40 mg bazedoxifene (1.59) group.
Stopa prolaznih ishemijskih ataka (TIA) na 1000 žena-godina bila je podjednaka u skupinama koje su primale bazedoksifen u dozi od 20 mg (1,1) odnosno placebo (0,88), a veći u skupini koja je primala bazedoksifen u dozi od 40 mg (1,59).
The rate per patient year of exposure (percentage of patients) of severe hypoglycaemia was 0.01 (1 patient out of 291) for Xultophy and 0.00 (0 patients out of 199) for GLP-1 receptor agonists.
Stopa teške hipoglikemije po bolesnik-godini izloženosti (postotak bolesnika) bila je 0,01 (1 bolesnik od 291) za Xultophy i 0,00 (0 bolesnika od 199) za agonist GLP-1 receptora .
The rate should be determined by the patient’s comfort level.
Brzinu infuzije treba odrediti prema razini podnošljivosti bolesnika.
The rate was highest in patients who were administered Herceptin concurrently with a taxane (2.0 %).
Učestalost je bila najviša u bolesnika koji su Herceptin primali istodobno s taksanima (2,0%).
The rates (events per patient year of exposure) of severe hypoglycaemia (ISPAD definition; 0.51 vs 0.33), confirmed hypoglycaemia (57.71 vs 54.05) and nocturnal confirmed hypoglycaemia (6.03 vs 7.60) were comparable with Tresiba versus insulin detemir.
Stope (događaj po bolesnik-godina izloženosti) teških hipoglikemija (definicija ISPAD; 0,51 prema 0,33), potvrđenih hipoglikemija (57,71 prema 54,05) i noćnih potvrđenih hipoglikemija (6,03 prema 7,60) bile su usporedive s lijekom Tresiba naspram detemir inzulina.
The rates (events per patient-year of exposure) of confirmed hypoglycaemia (ISPAD 2009 definition: 46.23 vs 49.55) and nocturnal confirmed hypoglycaemia (5.77 vs 5.40) were comparable with Ryzodeg versus insulin detemir whereas the rate of severe hypoglycaemia (0.26 vs 0.07) was higher in the Ryzodeg arm although the difference was not statistically significant.
Stope (događaji po bolesnik-godini izloženosti) potvrđene hipoglikemije (prema ISPAD definiciji iz 2009.: 46,23 naspram 49,55) i noćne potvrđene hipoglikemije (5,77 naspram 5,40) bile su usporedive u skupini koja je primala Ryzodeg i onoj koja je primala detemir inzulin, dok je stopa teške hipoglikemije bila viša u skupini koja je primala Ryzodeg (0,26 naspram 0,07) iako razlika nije bila statistički značajna.
The rates for congenital malformations (major and minor combined) reported for infants born after an FTET cycle (16.4%) were similar to those reported for infants born after fresh ART cycles (19.5%).
Stope kongenitalnih malformacija (kombinirane značajne i manje značajne) prijavljene za dojenčad rođenu nakon FTET ciklusa (16,4 %) bile su slične onima prijavljenima za dojenčad rođenu nakon stimuliranih ciklusa medicinski potpomognute oplodnje gdje embriji nisu bili smrznuti (19,5%).
The rates of acute rejection, graft loss, and death were similar at 1 and 2 years.
Stopa akutnog odbacivanja, gubitka presatka i smrti bila je slična nakon 1 i 2 godine.
The rates of acute rejection, graft loss, and death were similar, but urinary protein excretion was increased in the Rapamune treatment arm of this subset.
Stope akutnog odbacivanja, gubitka presatka i smrti bile su slične, ali je izlučivanje proteina u urinu bilo povećano u bolesnika u ovoj podskupini koji su liječeni Rapamuneom.
The rates of adverse reactions leading to permanent treatment discontinuation were 11% for the ONIVYDE+5-FU/LV arm and 12% for the monotherapy arm.
Stopa nuspojava koje su vodile trajnom prekidu liječenja bila je 11% za skupinu ONIVYDE+5-FU/LV odnosno 12% za skupinu s monoterapijom.
The rates of discontinuation due to any adverse reaction were 7.2% in patients receiving INTELENCE and 5.6% in patients receiving placebo.
Učestalosti prekida primjene lijeka zbog nuspojava bile su 7,2% u bolesnika koji su primali INTELENCE i 5,6% u bolesnika koji su primali placebo.
The rates of gout flare requiring treatment were low and comparable to placebo in the last 6 months of the randomised trials (after gout flare prophylaxis was discontinued) with median scores of zero.
Stope akutnih napadaja gihta koje je potrebno liječiti bile su niske i usporedive s placebom u posljednjih 6 mjeseci randomiziranih ispitivanja (nakon što je prekinuto profilaktičko liječenje akutnih napadaja), uz medijan rezultata jednak nuli.
The rates of Grade 3-4 IRRs (which occurred in relatively few patients) were similar before and after mitigation measures were implemented.
Stope reakcija na infuziju 3. – 4. stupnja (koje su nastupile u razmjerno malog broja bolesnika) bile su slične i prije i nakon provedbe profilaktičkih mjera.
The rates of MMR in the SPRYCEL and imatinib treatment groups, respectively, within 3 months (8% and 0.4%), 6 months (27% and 8%), 9 months (39% and 18%),
Stope MMR u terapijskoj skupini koja je primala SPRYCEL odnosno imatinib unutar 3 mjeseca (8% odnosno 0,4%), 6 mjeseci (27% odnosno 8%), 9 mjeseci (39% odnosno 18%), 12 mjeseci (46% odnosno 28%), 24 mjeseca (64% i
The rates of premature study discontinuation, adverse events overall (and infections, specifically), and biopsy-proven acute liver graft rejection at 12 months were all significantly greater in the sirolimus conversion group compared to the CNI continuation group.
Stope prijevremenog prekida ispitivanja, sve nuspojave (te posebno infekcije) i akutno odbacivanje presađene jetre dokazano biopsijom nakon 12 mjeseci u skupini u kojoj je inhibitor kalcineurina zamijenjen sirolimusom bile su znatno više u skupini koja je primala sirolimus nego u skupini u kojoj je nastavljena primjena inhibitora kalcineurina.
The rates of response for the two treatment arms are reported in Table 10.
Stope odgovora u oba kraka liječenja prikazane su u Tablici 10.
The rates of treatment-related adverse events resulting in discontinuation were 14% in CP-CML, 7% in AP-CML and 4% in BP-CML/Ph+ ALL.
Stope nuspojava povezanih s liječenjem koje su rezultirale u prekidu liječenja iznosile su 14% u CP-KML, a 7% u AP-KML te 4% u BP-KML/Ph+ALL.
The ratio of mitogenic relative to metabolic potency for insulin degludec is comparable to that of human insulin.
Omjer mitogenog i metaboličkog potencijala degludek inzulina, usporediv je s onim za humani inzulin.
The ratio of patients with basal versus squamous cell skin cancers (4:1) is comparable with the ratio expected in the general population (see section 4.4).
Omjer bolesnika sa bazocelularnim u odnosu na planocelularni karcinom kože (4:1) može se usporediti s omjerom očekivanim u općoj populaciji (vidjeti dio 4.4).
The ratio of the exacerbation rate for fluticasone furoate/vilanterol 92/22 micrograms versus FF 92 was 0.755 (95% CI 0.603, 0.945).
Omjer stope egzacerbacije za flutikazonfuroat/vilanterol od 92/22 mikrograma u odnosu na flutikazonfuroat od 92 mikrograma iznosio je 0,755 (95% CI 0,603; 0,945).
The rational basis for treatment consists of restoration of the bile acid- dependent component of bile flow enabling restoration of biliary secretion and biliary elimination of toxic metabolites; inhibition of the production of the toxic bile acid metabolites by negative feedback on cholesterol 7α-hydroxylase, which is the rate-limiting enzyme in bile acid synthesis; and improvement of the patient’s nutritional status by correcting intestinal malabsorption of fats and fat-soluble vitamins.
Racionalna osnova za liječenje sastoji se od obnavljanja komponente protoka žuči ovisne o žučnoj kiselini čime se omogućuje obnova žučne sekrecije i bilijarne eliminacije toksičnih metabolita, inhibicija nastanka toksičnih metabolita žučne kiseline negativnom povratnom spregom na kolesterol 7α-hidroksilazu, enzim koji ograničava brzinu sinteze žučne kiseline i poboljšanje nutritivnog statusa bolesnika ispravljanjem intestinalne malapsorpcije masti i vitamina topivih u mastima.